| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w14567 |
| 来源ID | Working Paper 14567 |
| Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy | |
| Vincenzo Atella; Jay Bhattacharya; Lorenzo Carbonari | |
| 发表日期 | 2008-12-11 |
| 出版年 | 2008 |
| 语种 | 英语 |
| 摘要 | This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a simple model of adverse selection we model the interaction between firms, heterogeneous buyers and the regulator. The theoretical analysis provides two results. First, an MES regime provides greater incentives to produce high quality drugs. Second, an MES+PC mix reduces the difference in price between the highest and lowest quality drugs on the market. The empirical analysis based on US and Italian data corroborates these results. |
| 主题 | Health, Education, and Welfare ; Health ; Industrial Organization ; Regulatory Economics ; Industry Studies |
| URL | https://www.nber.org/papers/w14567 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/572241 |
| 推荐引用方式 GB/T 7714 | Vincenzo Atella,Jay Bhattacharya,Lorenzo Carbonari. Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy. 2008. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w14567.pdf（376KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
